Featured Articles

  1. Early-Stage Biotech's AI Advantage Is A Window That Closes 5/27/2026

    FDA AI guidance won’t build your strategy for you. Learn how biotech teams can avoid retrofits and design smarter clinical AI from day one.

  2. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

    FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

  3. Where PRO Strategy Goes Wrong 5/27/2026

    PRO and COA strategy is now central to trial success. Organizations that capture meaningful patient experience data will gain stronger evidence and a regulatory advantage.

  4. Is The Industry Ready To Trust LLMs With Chart Review? 5/27/2026

    See how LLM-powered extraction transforms unstructured medical records into compliant, audit-ready clinical data with machine-scale speed, human oversight, and regulatory-grade accuracy.

  5. The eCOA Iceberg 5/27/2026

    Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

  6. Optimizing Data Capture From Protocol Design To Efficacy Endpoints 5/6/2026

    The shift to digital trials favors the 11-point NRS over the traditional VAS to reduce data noise, improve elderly patient compliance, and ensure statistical power across mobile devices.

  7. Own Your Data, Accelerate Your Cure 5/6/2026

    Move from passive donor to active innovator. Explore how patient communities are building their own research infrastructure and using AI to bypass traditional barriers to drug development.

  8. A Blueprint For Modern Obesity Research 5/6/2026

    The landscape of obesity and GLP-1 research has reached a saturation point. To successfully scale to the 5,000-patient registries now required for long-term evidence, a shift in operational architecture is essential.

  9. Strong Bookings And The Disruption Gap Nobody Is Talking About 5/6/2026

    Understand the real impact of AI on CRO valuations and clinical trial stability. Explore why market data contradicts the "disruption" narrative and what it means for the future of the industry.

  10. Early-Stage Biotech's AI Advantage Is A Window That Closes 5/6/2026

    The "greenfield" advantage allows biotechs to build AI-native trials from the start, replacing manual data entry with automated workflows and structured human oversight for better data integrity.